GLUE
Monte Rosa Therapeutics Inc
$
4.440
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.660
Open
4.520
VWAP
4.54
Vol
451.12K
Mkt Cap
274.21M
Low
4.415
Amount
2.05M
EV/EBITDA(TTM)
-0.68
Total Shares
61.15M
EV
-15.76M
EV/OCF(TTM)
-0.57
P/S(TTM)
2.06
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
1.33M
-98.43%
-0.480
-184.21%
20.21M
-66.67%
-0.205
-176.09%
9.36M
+1.6%
-0.315
+8.58%
Estimates Revision
The market is revising No Change the revenue expectations for Monte Rosa Therapeutics, Inc. (GLUE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 9.90%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+9.90%
In Past 3 Month
4 Analyst Rating
316.67% Upside
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 18.50 USD with a low forecast of 17.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
316.67% Upside
Current: 4.440
Low
17.00
Averages
18.50
High
20.00
316.67% Upside
Current: 4.440
Low
17.00
Averages
18.50
High
20.00
Wedbush
Robert Driscoll
Buy
Maintains
$15 → $17
2025-03-21
Reason
Wedbush
Robert Driscoll
Price Target
$15 → $17
2025-03-21
Maintains
Buy
Reason
Wedbush raised the firm's price target on Monte Rosa Therapeutics to $17 from $15 and keeps an Outperform rating on the shares after the company reported Q4 financials and provided clinical updates for its VAV1 and MRT-2359 programs in immunology and oncology, respectively. Monte Rosa shared healthy volunteer data for its MRT-6160 VAV1 degrader program showing a favorable safety profile, along with deep VAV1 degradation of over 90% and substantial ablation of T and B cell function shown by reduction in cytokine release from T and B cells following ex vivo stimulation, the firm notes. Taken together, Wedbush sees these data as providing robust support for further evaluation of the molecule in Phase 2 studies in immune mediated diseases, including autoimmune indications such as colitis and rheumatoid arthritis.
Wells Fargo
Derek Archila
Hold
Maintains
$11 → $10
2025-03-21
Reason
Wells Fargo
Derek Archila
Price Target
$11 → $10
2025-03-21
Maintains
Hold
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Monte Rosa Therapeutics to $10 from $11 and keeps an Equal Weight rating on the shares. The firm likes the progress on MRT-6160 and believes it increases the odds of future milestones and royalties. That said, Monte Rosa Therapeutics' programs remain early and with limited catalysts in the near term, Wells expects shares to be range bound.
Wells Fargo
Derek Archila
Buy
to
Hold
Downgrades
$14 → $11
2024-12-19
Reason
Wells Fargo
Derek Archila
Price Target
$14 → $11
2024-12-19
Downgrades
Buy
to
Hold
Reason
Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock's upside is limited in 2025 given MRT-6160 is now partnered and the MRT-2359 Phase 1 update in Q1 may have too few patients to fully interpret its profile. As such, Monte Rosa shares are likely to be range bound in 2025, the analyst tells investors in a research note.
Wedbush
Robert Driscoll
Buy
Reiterates
$11
2024-09-12
Reason
Wedbush
Robert Driscoll
Price Target
$11
2024-09-12
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Monte Rosa Therapeutics Inc (GLUE.O) is -2.77, compared to its 5-year average forward P/E of -4.64. For a more detailed relative valuation and DCF analysis to assess Monte Rosa Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.64
Current PE
-2.77
Overvalued PE
-1.10
Undervalued PE
-8.19
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.65
Current EV/EBITDA
-0.27
Overvalued EV/EBITDA
1.94
Undervalued EV/EBITDA
-7.24
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
9.41
Current PS
8.03
Overvalued PS
22.38
Undervalued PS
-3.56
Financials
Annual
Quarterly
FY2025Q2
YoY :
+394.01%
23.19M
Total Revenue
FY2025Q2
YoY :
-52.35%
-15.55M
Operating Profit
FY2025Q2
YoY :
-59.44%
-12.30M
Net Income after Tax
FY2025Q2
YoY :
-65.12%
-0.15
EPS - Diluted
FY2025Q2
YoY :
+22.24%
-36.42M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
13.40
FCF Margin - %
FY2025Q2
YoY :
-91.79%
-53.01
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
12.3M
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
1
58.4K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
3.1M
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
1
1.8M
Volume
Months
3-6
2
3.2M
Volume
Months
6-9
1
2.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
12.3M
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
1
58.4K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GLUE News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
07:22:56
Monte Rosa Therapeutics reports Q2 revenue $23.194M, consensus $7.37M
2025-07-21 (ET)
2025-07-21
07:11:01
Monte Rosa announces first subjects dosed in Phase 1 study of MRT-8102
2025-06-10 (ET)
2025-06-10
07:06:16
Monte Rosa Therapeutics announces FDA clearance of IND application for MRT-8102
Sign Up For More Events
Sign Up For More Events
News
4.0
08-12NASDAQ.COMValidea Kenneth Fisher Strategy Daily Upgrade Report - 8/12/2025
9.0
07-03NewsfilterMonte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
5.0
03-25NASDAQ.COMInsider Purchase: Director at $GLUE Buys 10,000 Shares
Sign Up For More News
People Also Watch
RR
Richtech Robotics Inc
2.150
USD
+1.42%
KLTR
Kaltura Inc
1.630
USD
+1.24%
LOCO
El Pollo Loco Holdings Inc
10.690
USD
+2.99%
NEWT
NewtekOne Inc
12.300
USD
+2.67%
TBRG
TruBridge Inc
20.010
USD
+2.20%
EB
Eventbrite Inc
2.650
USD
+4.33%
KRRO
Korro Bio Inc
18.930
USD
+18.39%
HRTG
Heritage Insurance Holdings Inc
22.080
USD
+1.75%
IHRT
iHeartMedia Inc
2.200
USD
+8.37%
QTRX
Quanterix Corp
4.790
USD
+0.63%
FAQ
What is Monte Rosa Therapeutics Inc (GLUE) stock price today?
The current price of GLUE is 4.44 USD — it has decreased -0.22 % in the last trading day.
What is Monte Rosa Therapeutics Inc (GLUE)'s business?
What is the price predicton of GLUE Stock?
What is Monte Rosa Therapeutics Inc (GLUE)'s revenue for the last quarter?
What is Monte Rosa Therapeutics Inc (GLUE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Monte Rosa Therapeutics Inc (GLUE)'s fundamentals?
How many employees does Monte Rosa Therapeutics Inc (GLUE). have?